Quanterix price target lowered to $20 from $25 at Canaccord

Canaccord lowered the firm’s price target on Quanterix to $20 from $25 and keeps a Buy rating on the shares. The company reduced 2024 revenue guidance as macro headwinds remain, the analyst tells investors in a research note. The firm says that although customer adoption of Quanterix’s new assays remains relatively low, the company is committed to launching 20 new assays overall in 2024 and improving adoption over time.